Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on X:
“Hot off the press!
Pleased to share our commentary in ASCO Journal of Clinical Oncology in the Comments and Controversies section “Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review”.
Why traditional RCT-focused reviews may miss the mark in Precision Medicine era.
Time to evolve our evidence frameworks!”
Title: Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review
Authors: Vivek Subbiah and Razelle Kurzrock
More featuring V. Subbiah.